SCHEMBL651298

SCHEMBL651298

O=S(=O)(NC1Cc2cc(-c3ccc(F)cc3)ccc2N(Cc2ccccc2)C1)c1ccc(Cl)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 6/20 0.43
PSEN2 P49810 6/20 0.43
APH1B Q8WW43 6/20 0.43
NCSTN Q92542 6/20 0.43
APH1A Q96BI3 6/20 0.43
PSENEN Q9NZ42 6/20 0.43
HTR7 P34969 8/20 0.42
HTR1A P08908 6/20 0.42
DRD2 P14416 5/20 0.42
HTR6 P50406 5/20 0.42
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
F10 P00742 1/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651315 0.86 FNTA (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL651273 0.86 FNTA (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL651274 0.86 FNTA (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL650754 0.85 NR1H2 (0.47) MTNR1AMTNR1BALDH1A1GAAKMT2A
SCHEMBL651439 0.84 FNTA (0.44) HTR7HTR1ADRD2MTNR1AMTNR1B
SCHEMBL650432 0.83 FNTA (0.38) MTNR1AMTNR1BALDH1A1GAAKMT2A
SCHEMBL650565 0.83 HTR1A (0.46) HTR7HTR1ADRD2HTR6MTNR1A
SCHEMBL649304 0.83 FNTA (0.45) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL650945 0.82 FNTA (0.47) HTR7HTR1ADRD2HTR6MTNR1A
SCHEMBL650258 0.82 MTNR1A (0.42) DRD2MTNR1AMTNR1BALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 US claimed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US claimed
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-20 US claimed
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 US disclosed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-7884113-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-08 US disclosed
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 US disclosed
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 PSEN1 515/4885PSEN2 776/4885APH1B 259/4885
US-20050014786-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators CNR2, CNR1, OPRL1 PSEN1 515/4885PSEN2 776/4885APH1B 259/4885
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 PSEN1 515/4885PSEN2 776/4885APH1B 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.